Compound Name: CLS-AX, axitinib injectable suspension 
Protocol Number: CLS1002-101 
IND Number: 132228 
Study ID: [REMOVED] 
Protocol Title OASIS: Open-label, dose-escalation, phase 1/2a study of 
the safety and tolerability of suprachoroidally administered 
CLS-AX following intravitreal anti-VEGF therapy in 
subjects with neovascular age-related macular degeneration 
Sponsor: Clearside Biomedical, Inc. 
900 North Point Parkway, Suite 200 
Alpharetta, GA 30005 
Issue Date: Protocol Amendment 1 Date: Protocol Amendment 2 Date: 
Protocol Amendment 3 Date: 
Protocol Amendment 4 Date: 15 October 2020 
26 March 2021 13 December 2021 
08 March 2022 
15 April 2022 
 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 Clinical Protocol
Amendment 4 Summary of Changes 15 April 2022 Page 1of 5 
CONFIDENTIALA. SUMMARY OF CHANGES
Protocol Amendment 4
Protocol Title: OASIS : OPEN-LABEL, DOSE-ESCALATION, PHASE 1/2A STUDY OF THE SAFETY AND 
TOLERABILITY OF SUPRACHOROIDALLY ADMINISTERED CLS-AX FOLLOWING 
INTRAVITREAL ANTI-VEGF THERAPY IN SUBJECTS WITH NEOVASCULAR AGE-RELATED 
MACULAR DEGENERATION
Protocol Number:
IND:CLS1002-101 
132228 Original Version Date: 15 October 2020 
Amendment Number: 4 Version Number and Date: Version 5, 15 April 2022 
Note: for clarity, deleted text will be denoted with a strikethrough and additional/altered text will appear in bold . 
Minor editorial changes to improve readability will not be documented.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 1of 76 
CONFIDENTIALProject: 1002 
Compound Number/Name: CLS-AX (axitinib injectable suspension)  
Protocol Number: CLS1002-101 
IND Number: 132228 
Phase: 1/2a 
Protocol Title: OASIS: OPEN-LABEL, DOSE-ESCALATION, PHASE 1/2A 
STUDY OF THE SAFETY AND TOLERABILITY OF 
SUPRACHOROIDALLY ADMINISTERED CLS-AX 
FOLLOWING INTRAVITREAL ANTI-VEGF THERAPY IN SUBJECTS WITH NEOVASCULAR AGE-RELATED 
MACULAR DEGENERATION
Sponsor: Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200 
Alpharetta, GA 30005
Primary Medical Monitor: Benjamin I. Rubin, M.D. 
Principal Investigator: To be appointed before the end of the study
Protocol Amendment 4 Date: 
Protocol Amendment 3 Date: Protocol Amendment 2 Date: 
Administrative Change Date: 
Protocol Amendment 1 Date:
Issue Date:15 April 2022 
08 March 2022 13 December 2021 
19 November 2021 
26 March 2021 
15 October 2020 
CONFIDENTIAL
This protocol contains confidential information abou t a product provided by Clearside Biomedical, Inc.  
This information is provided for the exclusive use of  the Investigators participating in this study.  Any 
and all confidential information contained herein may not be disclosed to any other person or party 
without the prior written consent of Clearside Biomedical, Inc. 

CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 2of 76 
CONFIDENTIALSIGNATURE PAGE
This study protocol has been reviewed and appr oved by the undersigned persons. It is confirmed 
that the information and guidance given in this  protocol amendment complies with scientific 
principles, the guidelines of Good Clinical Practic es, the Declaration of Helsinki in the latest 
relevant version and the applicable legal and regulato ry requirements. 
Sponsor Signatory:
Thomas Ciulla, M.D.
Chief Medical OfficerClearside Biomedical, Inc.ELECTRONIC SIGNATURE 
ON FILE
Sponsor Signatory:
Barbara Bauschka
Vice President, Regulatory OperationsClearside Biomedical, Inc.ELECTRONIC SIGNATURE 
ON FILE
Sponsor Signatory:
Colette Hall, M.D.
Vice President, Medical and SafetyClearside Biomedical, Inc.ELECTRONIC SIGNATURE 
ON FILE
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 3of 76 
CONFIDENTIALINVESTIGATOR’S AGREEMENT
I have received and read the Investigator’s Brochure for CLS-AX (axitinib injectable 
suspension).  I have read the CLS1002-101 Protoc ol and agree to conduct the study as outlined.  
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
             
Printed Name of Investigator 
             
Signature of Investigator        
Date
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 4of 76 
CONFIDENTIALPROCEDURES IN CASE OF EMERGENCY
Table 1: Emergency Contact Information 
Role in Study Name Address and Telephone 
number
Clinical Study Leader Georgina Debrah Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200 
Alpharetta, GA 30005 
USA
(678) 254-2345 
Responsible Physician Thomas Ciulla , M.D. Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200 
Alpharetta, GA 30005 
USA
(678) 392-2318 
Drug Safety Physician Colette Hall, M.D. Clearside Biomedical, Inc.
900 North Point Parkway, 
Suite 200 
Alpharetta, GA 30005 
USA
(678) 820-4178 
Primary Medical Monitor(24-Hour Emergency Contact) Benjamin I. Rubin, 
M.D. MedTrials, Inc.
7801 Renoir Court 
Potomac, MD 
USA(301) 509-4451 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 5of 76 
CONFIDENTIALCLINICAL LABORATORIES AND MEDICAL INSTITUTIONS
Table 2: Names and Add resses of Institutions
Reading Center Name and Address
Central Laboratory ACM Global Laboratories 
160 Elmgrove Park 
Rochester, NY 14624 
USA
Electrocardiogram Reading Center Clario
1818 Market StreetSuite 2600 
Philadelphia, PA 19103-3600 
USA
Pharmacokinetic Evaluation Covance Laboratories
8211 SciCor Drive 
Indianapolis, IN 46214 
USA
Central Reading Center for Fundus Photographs, Fluorescein 
Angiograms and Spectral Domain Optical Coherence 
Tomography Merit CRO, Inc. 
6527 Normandy Lane 
 #100 
Madison, WI 53719 USA
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 6of 76 
CONFIDENTIALREVISION HISTORY
Table 3: Revision History
Version Number Date Revision summary 
Draft 19 May 2020 Initial release version for IND.
1.0 15 October 2020 Initial release of protocol.
2.0 26 March 2021 Protocol Amendment 1. 
2.1 19 November 2021 Admin istrative Change 1. 
3.0 13 December 2021 Protocol Amendment 2. 
4.0 08 March 2022 Protocol Amendment 3. 
5.0 15 April 2022 Protocol Amendment 4. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 7of 76 
CONFIDENTIAL2. SYNOPSIS
Name of Sponsor/Company:
Clearside Biomedical, Inc.
Name of Investigational Product:
CLS-AX (axitinib injectable suspension)
Name of Active Ingredient:
Axitinib
Title of Study: 
OASIS: Open-label, dose-escalation, phase 1/2a study of the safety and tolerability of 
suprachoroidally administered CLS-AX following in travitreal anti-VEGF therapy in subjects with 
neovascular age-related macular degeneration
Study centers: Multi-Center
Principal Investigators: Multi-Center
Studied period: 16 Week Duration
Estimated date first subject enrolled: December 2020 
Estimated date last subject completed: September 2022 Phase of development: 
Phase 1/2a 
Background and Rationale:Currently, anti-vascular endothelial growth factor (VEGF)-A drugs are the standard of care for the 
treatment of neovascular age-related macular degeneration (nAMD) ( Flaxel, 2020 ); however, an 
unmet need remains for significantly improving and maintaining visual acuity in most patients (Rofagha, 2013 ,CATT, 2016 ,Singer, 2012 ). 
Axitinib demonstrates intrinsic high potency a nd achieves pan-VEGF inhibition through tyrosine 
kinase receptor blockade ( INLYTA, 2018 ,Hu-Lowe, 2008 ); axitinib is a second-generation tyrosine 
kinase inhibitor (TKI) that potently inhibits vasc ular endothelial growth factor receptors VEGFR-1, 
VEGFR-2, and VEGFR-3 at picomolar concentrations, and inhibits platelet-derived growth factor 
receptors (PDGFR) and c-KIT receptors to a significantly lesser degree, by stabilizing the receptor kinase domain in an inactive conformation. In preclinical work by independent investigators, axitinib 
effectively inhibited corneal, retinal and choroidal angiogenesis in multiple preclinical models 
(Riquelme, 2018 ,Yuan, 2015 ,Giddabasappa, 2016
,Nakano, 2016 ,Kang, 2013 ).  Topical axitinib 
more effectively inhibited experimental corneal neovascularization than other topical tyrosine kinase 
receptor inhibitors in a preclinical model (Yuan, 2015).  Furthermore, experimental oral axitinib not 
only inhibited choroidal neovascularization, but  also caused regression of established 
neovascularization (Kang, 2013). Importantly, in-vitro assessment has revealed better 
biocompatibility with ocular cells than other tyrosine kinase inhibitors ( Thiele, 2013 ). 
Suprachoroidal (SC) injection is a novel drug-dispensing approach that is a minimally invasive office-
based procedure, performed using Clearside’s pr oprietary injection device, the SCS Microinjector®. A 
SC injection is the term used to describe this intraocular injection procedure performed in the pars plana approximately 4 – 4.5 mm posterior to the limbus, resulting in a sub-scleral dispensing of drug 
product into the suprachoroidal space (SCS) which is  the transition region between the sclera and the 
choroid.  Immediately after the SC injection procedure, injectate moves posteriorly from the site of 
the injection, with the fluid being absorbed dominan tly into the inner sclera, choroid, retinal pigment 
epithelial (RPE) cells, and retina. Clearside Biomedical Inc. (“Clearside”) is developing a proprietary 
formulation of axitinib, CLS-AX (axitinib injectable suspension) to treat nAMD by injection into the 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 15of 76 
CONFIDENTIAL3. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS
1. TITLE PAGE ................................................................................................................1  
INVESTIGATOR’S AGREEMENT ...............................................................................................3  
PROCEDURES IN CASE OF EMERGENCY ...............................................................................4  
2. SYNOPSIS ...................................................................................................................7  
3. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............15  
4. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................20  
5. INTRODUCTION ......................................................................................................22  
6. TRIAL OBJECTIVES AND PURPOSE ....................................................................26  
6.1. Primary Objective .......................................................................................................26  
6.2. Secondary Objectives .................................................................................................26  
6.3. Exploratory Objectives ...............................................................................................26  
7. INVESTIGATIONAL PLAN .....................................................................................27  
7.1. Overall Study Design ..................................................................................................27  
7.2. Endpoints ....................................................................................................................2 7 
7.2.1.  Primary Endpoint ........................................................................................................27  
7.2.2.  Secondary Endpoints ..................................................................................................27  
7.2.3.  Pharmacokinetic Endpoints ........................................................................................28  
7.3. Number of Subjects ....................................................................................................28  
7.4. Treatment Assignment ................................................................................................28  
7.5. Dose Adjustment Criteria ...........................................................................................29  
7.5.1.  Safety Criteria for Adjus tment or Stopping Doses .....................................................29  
7.5.2.  Pharmacokinetic Criteria for Ad justment or Stopping Doses ....................................29  
7.6. Criteria for Study Termination and Suspension .........................................................29  
7.6.1.  Early Discontinuation of the Study.............................................................................29  
7.6.2.  Suspension of the Study..............................................................................................29  
7.6.3.  Dose-Escalation Criteria .............................................................................................30  
8. SELECTION AND WITHDRAWAL OF SUBJECTS ..............................................32  
8.1. Subject Inclusion Criteria ...........................................................................................32  
8.2. Subject Exclusion criteria: ..........................................................................................33  
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 16of 76 
CONFIDENTIAL8.2.1.  Ophthalmic Exclusion Criteria ...................................................................................33  
8.2.2.  General Exclusion Criteria .........................................................................................34  
8.3. Subject Withdrawal Criteria .......................................................................................35  
8.4. Visit Procedure Description ........................................................................................36  
8.4.1.  General Pro cedures .....................................................................................................36  
8.4.2.  Rescreening Procedures ..............................................................................................36  
8.4.3.  Visit 1 – Screening (Day -28 ± 3 days) ......................................................................36  
8.4.3.1.  Aflibercept IVT Injection Procedure ..........................................................................38  
8.4.4.  Visit 2 - Baseline (Day 1) ...........................................................................................38  
8.4.4.1.  Visit 2 (Day 1) Pre CLS-AX Suprac horoidal Injection Procedures ...........................38  
8.4.4.2.  CLS-AX Suprachoroidal In jection Procedures ..........................................................39  
8.4.4.3.  CLS-AX Suprachoroidal Injecti on Post Dose Procedures .........................................40  
8.4.5.  Visits 3 and 4 (Weeks 4 and 8) ...................................................................................40  
8.4.5.1.  Additional IVT Aflibercept Procedure .......................................................................41  
8.4.5.2.  Post IVT Injection of Aflibercept ...............................................................................41  
8.4.6.  Visit 5 (Week 12) End of Study/Early Termination ...................................................42  
8.4.7.  Unscheduled Visits .....................................................................................................43  
9. TREATMENT OF SUBJECTS ..................................................................................44  
9.1. Treatment Regimen, Do sing, and Duration ................................................................44  
9.2. Study Eye Determination ............................................................................................44  
9.3. Fellow Eye Treatment .................................................................................................44  
9.4. Additional Treatment ..................................................................................................45  
9.4.1.  Additional Therapy Criteria ........................................................................................45  
9.5. Concomitant Medications ...........................................................................................45  
9.5.1.  Prohibited Medications ...............................................................................................45  
9.6. Treatment Compliance ................................................................................................46  
9.7. Randomization and Masking ......................................................................................46  
10. STUDY DRUG MATERIALS AND MANAGEMENT ...........................................47  
10.1.  Study Drug ..................................................................................................................47  
10.2.  Study Drug Packaging and Labeling ..........................................................................47  
10.3.  Study Drug Storage .....................................................................................................47  
10.4.  Study Drug Preparation ..............................................................................................47  
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 17of 76 
CONFIDENTIAL10.5.  Administration ............................................................................................................47  
10.6.  SCS Microinjector Use Questionnaire ........................................................................48  
10.7.  Study Drug Accountability .........................................................................................48  
10.8.  Study Drug Handling and Disposal ............................................................................48  
11. PHARMACOKINETIC ASSESSMENTS .................................................................49  
11.1.  Blood Sample Collection ............................................................................................49  
11.2.  Urine Sample Collection .............................................................................................49  
12. ASSESSMENT OF SAFETY .....................................................................................50  
12.1.  Safety Va riables ..........................................................................................................50  
12.1.1.  Best Corrected Visual Acuity .....................................................................................50  
12.1.2.  Spectral Domain Optical Coherence Tomography .....................................................50  
12.1.3.  Optical Coherence Tomo graphy Angiography ...........................................................50  
12.1.4.  Intraocular Pressure ....................................................................................................50  
12.1.5.  Slit-lamp Biomicroscopy ............................................................................................51  
12.1.5.1.  Cataract Lens Grading ................................................................................................51  
12.1.5.2.  Anterior Chamber Cells ..............................................................................................51  
12.1.5.3.  Anterior Chamber Flare ..............................................................................................51  
12.1.6.  Indirect Ophthalmoscopy ............................................................................................52  
12.1.6.1.  Vitreous Haze .............................................................................................................52  
12.1.7.  Fluorescein Angiography ............................................................................................52  
12.1.8.  Fundus Photography ...................................................................................................53  
12.1.9.  Vital Signs ..................................................................................................................5 3 
12.1.10.  Weight and Height ......................................................................................................53  
12.1.11.  Review of Body Systems (P hysical Examination) .....................................................53  
12.1.12.  12-Lead Electrocardiogram Assessment ....................................................................53  
12.1.13.  Laboratory Assessments .............................................................................................53  
12.1.13.1.  Pregnancy Screen ........................................................................................................54  
12.1.14.  Fundus Autofluorescence Imaging .............................................................................54  
12.2.  Adverse and Serious Adverse Events .........................................................................54  
12.2.1.  Definition of Adverse Events .....................................................................................54  
12.2.1.1.  Adverse Even t (AE) ....................................................................................................54  
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 18of 76 
CONFIDENTIAL12.2.1.2.  Clinical Laboratory Abnormalities and other Abnormal Assessments as 
Adverse Events and Seri ous Adverse Events .............................................................55  
12.2.1.3.  Serious Adverse Event (SAE) ....................................................................................55  
12.2.2.  Evaluating Adverse Events .........................................................................................56  
12.2.2.1.  Intensity/Severity Grade .............................................................................................56  
12.2.2.2.  Assessment of Causality .............................................................................................57  
12.2.3.  Recording Adverse Events .........................................................................................57  
12.2.4.  Reporting Adverse Events ..........................................................................................58  
12.2.5.  Follow-up of AEs and SAEs .......................................................................................58  
12.2.6.  Exposure in utero During Clinical Trials ...................................................................59  
12.2.7.  Complaint Handling ....................................................................................................59  
13. STATISTICS ..............................................................................................................61  
13.1.  Randomization ............................................................................................................61  
13.2.  Determination of Sample Size and Level of Significance ..........................................61  
13.3.  Subject Disposition and Demographic and Baseli ne Characteristics .........................61  
13.4.  Analysis Populations ..................................................................................................61  
13.4.1.  Safety Population ........................................................................................................61  
13.4.2.  Pharmacokinetic Population .......................................................................................61  
13.5.  Analysis Methods .......................................................................................................61  
13.5.1.  Schedule of Analyses ..................................................................................................62  
13.5.2.  Safety Analysis ...........................................................................................................62  
13.5.3.  Secondary Safety Analyses .........................................................................................63  
13.5.4.  Subgroup Analysis ......................................................................................................63  
13.5.5.  Interim Analysis ..........................................................................................................63  
13.5.6.  Pharmacodynamic Analysis........................................................................................63  
13.5.7.  Pharmacokinetic Analysis ..........................................................................................63  
13.5.8.  Procedure for Accounting for Missing Data ...............................................................63  
14. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS.........................................64  
14.1.  Study Monitoring ........................................................................................................64  
14.2.  Audits and Inspections ................................................................................................64  
14.3.  Institutional Review Board (IRB) ...............................................................................65  
15. QUALITY CONTROL AND QUALITY ASSURANCE .........................................66  
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 19of 76 
CONFIDENTIAL16. ETHICS ......................................................................................................................67  
16.1.  Ethics Review .............................................................................................................67  
16.2.  Ethical Conduct of the Study ......................................................................................67  
16.3.  Written Informed Consent ..........................................................................................67  
17. DATA HANDLING AND RECORDKEEPING .......................................................69  
17.1.  Case Report Forms/Elect ronic Data Record ...............................................................69  
17.2.  Inspection of Records .................................................................................................69  
17.3.  Retention of Records ..................................................................................................69  
18. FINANCING AND INSURANCE .............................................................................70  
18.1.  Finance ....................................................................................................................... .70 
18.2.  Insurance ..................................................................................................................... 70 
19. PUBLICATION POLICY ..........................................................................................71  
20. REFERENCES ...........................................................................................................72  
21. APPENDICES ............................................................................................................75  
APPENDIX A:  TIME AND EVENTS SCHEDULE .................................................................75  
LIST OF TABLES
Table 1:  Emergency Contact Information ...................................................................................4  
Table 2:  Names and Addresses of Institutions ............................................................................5  
Table 3:  Revision History ...........................................................................................................6  
Table 4:  Abbreviations and Specialist Terms ...........................................................................20  
Table 5:  Dose Cohorts ..............................................................................................................28  
Table 6:  Anterior Chamber Cells Grading Scale ......................................................................51  
Table 7:  Anterior Chamber Fl are Gradin g Scale ......................................................................52  
Table 8:  Scale for Determining Degr ee of Vitreous Haze ........................................................52  
Table 9:  Clinical Laboratory Analytes to be Tested .................................................................54  
Table 10:  CTCAE Intensity Grades ............................................................................................56  
LIST OF FIGURES
Figure 1:  Study Treatment Schedule ..........................................................................................29  
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 20of 76 
CONFIDENTIAL4. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
The following abbreviations and specialist terms are used in this study protocol. 
Table 4: Abbreviations and Specialist Terms
Abbreviation or Specialist Term Explanation 
AE Adverse event 
AMD Age-related macular degeneration
BCVA Best corrected visual acuity
BSS Balanced saline solution
CABG Coronary artery bypass surgery 
Cmax Maximum serum concentration 
CNV Choroidal neovascularization
CRF Case report form
CST Central subfield retinal thickness 
CTCAE Common Terminology Criteria for Adverse Events 
CVA Cerebrovascular accident
DLT Dose limiting toxicity
ECG Electrocardiogram
ETDRS Early Treatment Diabetic Retinopathy Study 
FA Fluorescein angiogram
GCP Good Clinical Practice
GI Gastrointestinal
IB4 isolectin B 4
IC50 50% inhibitory concentration
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IOP Intraocular pressure 
IRB Institutional Review Board 
IVT Intravitreal(ly)
nAMD Neovascular age-related macular degeneration
NCI National Cancer Institute
NVI Neovascularization of the iris
NYHA New York Health Association
MedDRA Medical Dictionary for Regulatory Applications 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 21of 76 
CONFIDENTIALTable 4: Abbreviations and Specialist Terms (Continued)
Abbreviation or Specialist Term Explanation 
OCT-A Optical coherence tomography angiography 
PCV Polypoidal choroidal vasculopathy 
PD Pharmacodynamics 
PDGFR Platelet-derived growth factor receptor
PK Pharmacokinetics
PRN Pro re nata; “when necessary”
PSVT Paroxysmal supraventricular tachycardia
PTCA Percutaneous transluminal coronary angioplasty 
RAP Retinal angiomatous proliferation
RPE Retinal pigment epithelial
SAE Serious adverse event
SC Suprachoroidal 
SCS Suprachoroidal space 
SD-OCT Spectral Domain Optical Coherence Tomography 
SMC Safety Monitoring Committee 
SOC Systemic organ class
SVT Supraventricular tachycardia
TEAE Treatment-emergent adverse event
TKI Tyrosine kinase inhibitor
VA Visual acuity
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor
YAG Yttrium-Aluminum-Garnet
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 22of 76 
CONFIDENTIAL5. INTRODUCTION
In developed countries, neovascul ar age-related macular degenera tion (nAMD) is the leading 
cause of irreversible central blindness ( Congdon, 2004 ,The Eye Disease Prevalence Research 
Group, 2004 ,Wong, 2014 ). Age-related macular degenerati on (AMD) pathogenesis is complex 
and still not fully understood. However, many of th e mechanisms involved are already partially 
known and, specifically for the 10-15% of AMD cla ssified as the neovascular type, include the 
vascular endothelial gr owth factor (VEGF) signaling path way. In nAMD, a bnormal blood vessel 
growth results in choroidal neovascularization (CNV) in the choriocapillaris, a layer of 
capillaries situated immediately below Bruch’s membrane, under the retina and macula. 
Choroidal neovascularization lead s to the leakage of blood, lipids, and serum into the retinal 
layers and causes the macula to  bulge or lift up from its norma l position, distorting or destroying 
central vision ( Ambati, 2003 ). In nAMD, VEGF-A, which acts at VEGF receptors 1 and 2 
(VEGFR-1, VEGFR-2), has been shown to pr omote abnormal blood ve ssel growth and is 
therefore an appropriate target for treatment.
Currently, anti-VEGF-A drugs are the standa rd of care for the treatment of nAMD ( Flaxel, 
2020 ); however, an unmet need remains for si gnificantly improving and maintaining visual 
acuity in most patients ( Rofagha, 2013 ,CATT, 2016 ,Singer, 2012 ). Specifically, there may be a 
ceiling of efficacy with current anti-VEGF-A agents, as increased anti-VEGF-A dosage or more 
intense regimens yield no a dditional best corrected visu al acuity (BCVA) benefit ( Heier, 2012 ,
Busbee, 2013 ,Schmidt-Erfurth, 2014 ).  Recent data on VEGF regulation may be relevant, as 
anti-VEGF-A therapy has been shown to upregulate other members of the VEGF family in both 
macular degeneration ( Cabral, 2018 ) and colon cancer patients ( Lieu, 2013 ); this secondary 
upregulation of other members of the VEGF family may account for "resistance" to VEGF-A
therapy (Lieu, 2013). Furthermore, the current trea tment paradigm of freq uent intravitreal (IVT) 
injections is burdensome. For example, recent la rge “real-world” retrospective studies of nAMD 
demonstrated that patients are undertreated receiving only 6 to 7 injections on average, yielding 
only a mean 1 to 3 letters gained in BCVA one year after initiation of treatment ( Ciulla, 2020 ,
Rao, 2018 ).
Axitinib demonstrates intrinsic high potency and achieves pan-VEGF inhibition through tyrosine 
kinase receptor blockade ( INLYTA, 2018 ,Hu-Lowe, 2008 ); it is a second-generation tyrosine 
kinase inhibitor (TKI) that inhibits vascular  endothelial growth factor receptors VEGFR-1, 
VEGFR-2, and VEGFR-3 at picomolar concentrati ons, and inhibits platelet-derived growth 
factor receptors (PDGFR) and c-Kit receptors to a significantly lesser degree, by stabilizing the 
receptor kinase domain in an inactive conformati on.  Axitinib is currently approved in an oral 
tablet formulation (INLYTA®) for the treatment of  advanced renal cell carci noma after failure of 
1 prior systemic therapy.  In preclinical work by independent investigat ors, axitinib has shown 
promising results in animal models of ocular angiogenesis. Specifically, it effectively inhibited 
corneal, retinal and choroidal angiogenesis in multiple preclinical models ( Riquelme, 2018 ,
Yuan, 2015 ,Giddabasappa, 2016 ,Nakano, 2016 ,Kang, 2013 ).  Topical axitinib more effectively 
inhibited corneal neovascularizati on than other topical tyrosine kinase receptor inhibitors in a 
preclinical model (Yuan, 2015).  Furthermore, oral axitinib not only inhibited choroidal 
neovascularization, but also cause d regression of established neova scularization in a preclinical 
model (Kang, 2013), a highly desire d therapeutic effect for the treatment of human nAMD. In a 
cell culture study, axitinib consis tently exhibited superior ce ll viability among five different 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 23of 76 
CONFIDENTIALocular cell lines, even under conditions of oxidativ e stress, compared to other tyrosine kinase 
inhibitors previously assessed in nAMD clinical trials ( Thiele, 2013 ). 
Clearside Biomedical Inc. (“Cl earside”, “Sponsor”) is developi ng a proprietary formulation of 
axitinib, CLS-AX (axitinib injectable suspension) to treat nAMD by injection into the 
suprachoroidal space (SCS). Supr achoroidal (SC) injection is a novel drug-dispensing approach 
that employs the SCS Microinjector®, a proprietary piston syringe and a needle approximately 1 
mm in length. A SC injection is the term used to describe this intraocular injection procedure 
performed in the pars plana approximately 4 - 4.5 mm posterior to the limbus, resulting in sub 
scleral dispensing of drug  product into the SCS which is the transition region between the sclera 
and the choroid.  
Immediately after the SC injection procedure, in jectate moves posteriorly from the site of the 
injection, with the fluid being absorbed dominantl y into the inner sclera, choroid, retinal pigment 
epithelial (RPE) cells, and retina (based on anima l models). Suprachoroi dal injection of CLS-
AX, with a resulting ocular distribution of CL S-AX in high amounts into the choroid, RPE cells, 
and retina (based on data from animal models) pr ovides the potential for robust and sustained 
efficacy outcomes in patients with nAMD. While there is high exposure to CLS-AX in the retina, 
RPE cells, and choroid, there is also lower expos ure to CLS-AX in the anterior segment and the 
lens, providing the potential for a reduced incidence of ocular adverse events . Systemic levels of 
axitinib following SC injection are low to belo w the limits of quantification. Further, these 
systemic levels of axitinib are vastly below levels observed following oral administration of 
axitinib.  Suprachoroidal injection with Clearside’s SCS Microinjector has been evaluated in humans in the Sponsor’s clinical development pr ogram for an ocular corticosteroid (XIPERE™,
triamcinolone acetonide injectab le suspension, previously known as CLS-TA) for suprachoroidal 
use, approved in 2021 by the US FDA for the tr eatment of macular edem a associated with uveitis
(XIPERE Prescribing Information, 2021 ). Suprachoroidal injections  may be associated with 
increased ocular pressure at the time of injec tion, therefore subjects should be appropriately 
assessed following completion of the suprachoroida l injection.  Additionally, risks of ocular 
toxicity and/or inflammation have been mitigated through the single dose escalation design of 
this clinical trial, with an initial dose based on preclinical toxi cology studies in two species.  
Procedural risks, such as hemorrhage, inf ection, ocular hypertension, and retinal tear or 
detachment, have been assessed to be low and acc eptable in previous clinical studies with CLS-
TA, which have utilized the identical inject or design in over 1000 injection procedures.
Nonclinical pharmacodynamic (PD) studies de monstrate reduced fluorescein leakage and 
reduced growth of new blood vessels after SC in jection of CLS-AX, while  pharmacokinetic (PK) 
studies demonstrate durability via SC injecti on, supporting the potential to reduce treatment 
burden associated with frequent IVT injections. 
xIn a laser-induced porcine model of CNV, 8 pigs were administered SC injections of 4 
mg of CLS-AX in the right eye and balanced sa lt solution (BSS) in the left eye. At 1 and 
2 weeks after the laser-induced injury, the eyes treated with CLS-AX had a significantly 
smaller mean area of fluorescence compared to the BSS-treated eyes (P<0.009).  
Quantification of neovascularization was performed on retinal flat mount tissue by 
measuring the isolectin B
4(IB 4) signal. This analysis revealed that eyes treated with CLS-
AX had significantly lower IB 4 signal than BSS treated eyes (P=0.0297). 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 24of 76 
CONFIDENTIALxSimilar results were obtained in  a rat laser induced CNV m odel following SC injections 
of CLS-AX once weekly for 2 weeks. Decreases in the incidence of clinically important 
lesions (scores of 3 or 4) were noted in  animals given 0.4 mg/eye CLS-AX, where 8/20 
eyes (40%) showed a general improvement (sco res of 0 to 2) and attained statistical 
significance by Day 21, compared to 2/20 eyes  (10%) receiving control (saline). These 
results indicate that SC injection of CLS- AX significantly reduced  fluorescein leakage 
and growth of new blood vessels at the site of the retinal laser lesion as compared to 
saline treatment. 
With respect to PK, a 10-week study was perfo rmed in pigmented Dutch Belted rabbits to 
determine ocular tissue distribution after a singl e SC administration of CLS-AX. The injection 
was well tolerated. Retin al levels were ma intained above the in vitro  50% inhibitory 
concentration (IC50) with a SC injection of CLS-AX at 0.03 mg/eye and at 0.1 mg/eye for the 
entire duration of the study. 
Systemic absorption of axitinib following SC administration of CLS-AX was assessed in two 
non-GLP compliant 2-week single dose tolerability studies (with toxicokinetics (TK)) in rabbits 
and monkeys, one GLP compliant 4- week single dose toxicity studi es in rabbits (with TK and a 
26 week recovery period), and one GLP compliant  4-week single dose toxicity study in monkeys 
(with TK); all by SC injection. Plasma from bl ood collected from rabbits and monkeys during 
the conduct of 4-week toxicity studies was an alyzed using an LC-M S/MS method. The lower 
limit of quantification (LLOQ) was 2 ng/mL in both species. 
xIn the 2-week single dose rabbit toxicity study, CLS-AX was administered as a single 
unilateral SC injection (100 μL/right eye) to male New Zealand White rabbits 
(3/group) at 0 (vehicle), 0.4, 1.5, or 4.0 mg axitinib/right eye once on Day 1. Blood 
samples were collected on day 1 pre-dos e and 0.5, 1, 2, 4, 12, and 24 hours post-dose. 
Axitinib was below the LLOQ in all plasma samples except two samples (one animal 
given 1.5 mg/right eye [2.11 ng/mL] and one  animal given 4.0 mg/right eye [2.28 
ng/mL]) from the 1-hour time point. 
xIn the 4-week single dose rabbit toxicity study with a 26-week recovery phase, CLS-
$;ZDVJLYHQDVDVLQJOHELODWH UDO6&LQMHFWLRQȝ/H\HWR PDOHDQGIHPDOH
pigmented Dutch Belted rabbits  (5 animals/sex/group) at 0 (vehicle), 0.105, 1.05, or 
4.2 mg axitinib/eye once on day 1.  Blood sa mples were collected on day 1 pre-dose 
and 0.25, 0.5, 1, 6, 12, and 24 hours post-dose, and on days 28, 29 or 30, 60, 91, 120, and 150. Axitinib was detected in one plasma  sample (one animal given 4.2 mg/ eye 
[3.05 ng/mL]) from the 0.25-hour time point on Day 1. All other sa mples were below 
the LLOQ.
xIn the 2-week single dose monkey toxic ity study, CLS-AX was administered as a 
single unilateral SC  injection (100 μL/right eye) to male cynomolgus monkeys 
(2/group) at 0 (vehicle), 4.0, 6.0, or 8.0 mg axitinib/right eye once on Day 1. Blood 
samples were collected on day 1 pre-dos e, and 0.5, 1, 2, 4, 8, and 24 hours post-dose. 
Axitinib was not detected in any plasma sa mples at any intervals during this study.  
xIn the 4-week single dose monkey toxic ity study, CLS-AX was administered as a 
single unilateral SC injection (100 μL/right eye) to male and female cynomolgus 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 26of 76 
CONFIDENTIAL6. TRIAL OBJECTIVES AND PURPOSE
6.1. Primary Objective 
To assess safety and tolerability of a single dose of CLS-AX in subjects with neovascular age-
related macular degeneration who show stable visual acuity following >3 injections with an 
intravitreal anti-VEGF therapy in the preceding 5 months. 
6.2. Secondary Objectives
To evaluate and compare the effect of 4 coh ort regimens of a single dose of CLS-AX over 3 
months on visual function and ocular anatomy and the need for additional treatment with 
intravitreal aflibercept.
To evaluate the pharmacokinetics of the 4 c ohort regimens of a single dose of CLS-AX over 3 
months. 
6.3. Exploratory Objectives
To evaluate the safety and performance of the SCS Microinjector.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 31of 76 
CONFIDENTIALRecommendations for initiating the next higher cohort will be the responsibility of the SMC 
based on the totality of all ava ilable safety data.  Study drug ad ministration at the next higher 
dose cohort may not proceed until the Investigat or receives written confirmation from Clearside 
Biomedical, indicating the availabl e results from the previous dosed  cohort were evaluated and it 
is permissible to proceed to  the next higher dose cohort. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 43of 76 
CONFIDENTIAL8.4.7. Unscheduled Visits
To ensure subject safety during the study, a ny subject who requires additional follow-up or 
treatment for any reason at any time during the study that does not fall on a scheduled study visit 
should have that visit recorded as an Unsche duled Visit, unless the visit results in study 
discontinuation at which point an attempt should be  made to collect all Visit 5 assessments and 
the visit documented as such.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 46of 76 
CONFIDENTIALUse of the following treatments is pr ohibited at any time during the study: 
In cases where there is anticipated need for any of the treatments listed here during the study
(post Screening Visit), or if a subject presents  to the Investigator having initiated treatment 
during the study with one of these treatments, it is  the responsibility of the Investigator to notify 
the Sponsor immediately. If additional therapy is n ecessary to treat worsening of nAMD in the 
study eye and normal standard of care requires ad ditional intervention, the treatment(s) should be 
recorded in the subject’s source document( s) and CRF and should follow the guidelines 
presented for additional therapy criteria. S ubjects will not be discontinued from the study 
because of initiation of or cha nge in a prohibited medication. 
9.6. Treatment Compliance
Study medication will only be admin istered by trained study Investigators at the site.  No study 
medication will be dispensed to subjects; therefore, subject treatment compliance is not applicable.
9.7. Randomization and Masking
This is a Phase 1/2a dose-escala tion study.  Subjects will not be randomly assigned to a treatment 
or dose cohort. 
Enrollment of subjects into the next highe r dose cohort will not proceed until the SMC 
recommends initiation following review of all available safety data (Section 7.6.3 ). 
This is an open-label stu dy; no masking is necessary. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 51of 76 
CONFIDENTIALTonopens may be used for post-injection pressu re checks and in cases where no Goldmann is 
available.  The technician is encouraged to  use the same tonometry method throughout the 
subject’s study participation.  IOP will be meas ured 2 times at all visits in which a study 
treatment is administered including the IVT aflibercept injection at Screening (Visit 1), the CLS-
AX injection at Baseline (Visit 2), and any additional IVT aflibercept injection administered 
PRN at Visits 3 and 4 (Weeks 4 and 8):  before treatment and 10 to 30 minutes after treatment.Tonometers must be calibrated for accuracy before  the first subject screening at that site and 
according to the manufacturer specifications durin g the study, until the last subject has exited the 
study at that site. IOP will be assessed at all visits.
12.1.5. Slit-lamp Biomicroscopy
Slit-lamp biomicroscopy, including magnification, will be performed consistent with standard 
clinical practice. This procedure should be c onducted in the same manner for all subjects and 
will include an assessment of each of the followi ng as normal or abnorm al: eyelids, pupil and 
conjunctiva, cornea, anterior chamber, iris, a nd lens. All abnormal findi ngs will be described. 
Slit lamp examination of the iris is to rule out neovascularization of the iris (NVI). Slit lamp 
biomicroscopy will be as sessed at all visits.
12.1.5.1. Cataract Lens Grading 
If an abnormal finding of cataract  is noted during the slit-lamp examination, the cataract should 
be graded for nuclear opalescence, cortical op acity, and posterior subc apsular opacity. Graders 
must verify training on the grading procedures. Ca taract classification will be based on the Lens 
Opacities Classification System III (LOCS III) grading scale ( Chylack, 1993 ). Grading should be 
done by the same Investigator, whenever possi ble, on each subject per research site.
12.1.5.2. Anterior Chamber Cells
Anterior chamber cells will be assessed clinically using a field size of 1 mm slit beam and using 
a standardized grading scale ranging from  0 to 4+, as defined in Table 6 ( SUN, 2005 ).
Table 6: Anterior Cham ber Cells Grading Scale
Score Cells in Field
0< 1
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
12.1.5.3. Anterior Chamber Flare
Anterior chamber flare will be assessed clinically via slit lamp using a standardized scale ranging 
from 0 to 4+, as defined in Table 7  (SUN, 2005 ). 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 55of 76 
CONFIDENTIALundesirable medical condition occurring at any time , including baseline or washout periods, even 
if no study treatment ha s been administered. 
All AEs that occur after any subject has si gned informed consent, or during the study 
participation, whether or not th ey are related to the study drug, SCS Microinjector system or 
study procedure, must be recorded on the appropriate  form provided.  Each AE is to be evaluated 
for duration, intensity, and causal relationship with the study medication or other factors.
At every visit, patients should be asked about AEs in an open- ended manner as well as asked 
about the status of any previously reported AEs. 
When possible, a specific disease or syndrome rather than an individual associated sign or 
symptom should be identified by the Investigator  and recorded on the form.  If an observed or 
reported sign or symptom is not considered a com ponent of a specific disease or syndrome by the 
Investigator, it should be recorded as a separate AE on the form. 
NOTE: A significant or unexpected wo rsening or exacerbation of the condition/indication under 
investigation should be reported as  an AE.  However, anticipated day-to-day fluctuations or 
expected progression of the disease under inves tigation (based upon the Investigator’s clinical 
judgment) are not to be considered AEs. 
12.2.1.2. Clinical Laboratory Abnormalities and other Abnormal Assessments as Adverse 
Events and Serious Adverse Events
Abnormal laboratory findings (e .g., clinical chemistry, hematol ogy, and urinalysis) or other
abnormal assessments (e.g., ocular  assessments, ECGs, and vital signs) that are judged by the 
Investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition 
of an AE or SAE.  Clinically significant abnormal laboratory findi ngs or other abnormal 
assessments that are detected during the study or are present at baseline and significantly worsen 
following exposure to study drug are to be report ed as AEs or SAEs.  However, clinically 
significant abnormal laboratory fi ndings or other abnorma l assessments that are associated with 
the disease being studied, unless j udged by the Investigator as more severe than expected for the 
patient’s condition, or that are present at the st art of the study and do not worsen, should not be 
reported as AEs or SAEs. 
The Investigator will exercise medical and scientific  judgment in deciding whether an abnormal 
laboratory or assessment is clinically significant and if it requires reporting.
12.2.1.3. Serious Advers e Event (SAE)
An SAE is defined as an AE that meets any of the following criteria: 
xResults in death.
xIt is immediately life-threatening NOTE:  The term “life threatening” refers to an 
event in which the patient is at risk of death at the time of the event.  It does not refer to an event which hypothetically might ha ve caused death if it was more severe. 
xIt requires in-patient hosp italization or prol ongation of existing hospitalization.  
NOTE:  Hospitalization for an elective or procedure planned prior to the signing of 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 56of 76 
CONFIDENTIALthe informed consent to treat a preexisting condition is not considered an SAE unless 
it results in one of the other outcomes listed in this section.
xIt results in persistent or significant disability or incapacity.
xResults in a congenital a bnormality or birth defect. 
xIt is an important medical event that may jeopardize the patient or may require 
medical intervention to prevent one of the outcomes listed above. 
All SAEs that occur after any subject has signe d informed consent, whether or not they are 
related to the study, must be recorded on the forms provided. 
12.2.2. Evaluating Adverse Events 12.2.2.1. Intensity/Severity Grade
The intensity  of each AE will be graded using National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) v 4.03.  The criteria can be accessed at: 
https://ctep.cancer.gov/protocolDe velopment/electronic_applic ations/docs/CTCAE_v5_Quick_R
eference_5x7.pdf . 
It is important to distinguish between serious and severe AEs. Severity is  a measure of intensity 
whereas seriousness is defined by the criteria under Section 12.2.1.3 . An AE of severe intensity 
may not be considered serious. 
Grade refers to the intensity of the AE.  Th e CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of intensity for each AE based on this general guideline: 
Table 10: CTCAE Intensity Grades
Grade Description
Grade 1 Mild; asymptomatic or mild sy mptoms; clinical or diagnostic 
observations only; inte rvention not indicated 
Grade 2 Moderate; minimal, local, or noni nvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL)
Grade 3 Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of  the hospitalization indicated; 
disabling; limiting self-care ADL
Grade 4 Life-threatening consequences; urgent intervention indicated 
Grade 5 Death related to AE
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 57of 76 
CONFIDENTIAL12.2.2.2. Assessment of Causality 
The Investigator is responsible for making an a ssessment of the causal relationship between the 
AE and the study drug, drug delivery system, a nd/or study procedure based on the available 
information. 
The causal relationship of the AE is assessed us ing a binary system, and AEs are classified as 
either Related or Unre lated to the study drug, drug deliver y system, and/or study procedure. 
In assessing this relationship, the Investigator s hould consider the potential etiologies for the 
observed AE.  An AE may be related to: 
xThe study drug(s). 
xOther concomitant medications.
xUnderlying disease pathology. 
xA pre-treatment condition.
xA procedure performed in the course of the study. 
xOther alternative reason. 
Among the potential etiologies, the Investigator should make a determina tion based on the most 
likely causal relationship.  The causality assess ment provided for an AE or SAE should be 
accompanied by all available supporting eviden ce, including but not limited to supporting 
laboratory tests, histopathology, history of the presenting even t, medical history, temporal 
association, and results of re levant diagnostic procedures. 
12.2.3. Recording Adverse Events
Adverse events spontaneously reported by the su bject and/or in response to an open question 
from the study personnel or revealed by observatio n will be recorded during the study at the 
investigational site on the CRF.  Information about AEs will be collected from the time of 
signing of the consent form until 30 days af ter the end of study pa rticipatio n. Detailed 
information regarding all SAEs should be coll ected from the signing of the informed consent 
until the end of the study.  SAEs that are consid ered related to the use of study drug, the drug 
delivery system, and/or study procedure by the Inve stigator may be reporte d by the Investigator 
if they occur after the end of the study.  The Inve stigator must continue to follow the patient until 
the SAE has resolved, the conditi on has become chronic in nature , the condition stabilizes (in the 
case of persistent impairment), the patient experi ences a fatal outcome or is lost to follow up. 
The AE term should be reported in standard medi cal terminology as concisely as possible.  In 
general, the AE recorded should not be a procedure, outcome, or  clinical/laboratory 
measurement, but should reflect the event leading to the procedure, outcome or the cause of the 
clinical/laboratory abno rmality, if known.  Whenever possibl e, AEs should be evaluated and 
recorded as a diagnosis, rather than as individua l signs or symptoms.  However, if a definitive 
diagnosis is not possible, the individual signs a nd symptoms should be recorded.  For each AE, 
the Investigator will evaluate and report the onset (date and time), resolution (date and time), 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 58of 76 
CONFIDENTIALintensity, causality, action taken, seriousness, outcome (if applic able), and whether or not it 
caused the patient to discontinue the study .
12.2.4. Reporting Adverse Events
All AEs (related and unrelated) will be recorded from the signing of consent form until 30 days 
after the end of study participa tion.  All SAEs occurring during subject participation, and all 
SAEs considered related to the study drug, dr ug delivery system, and/or study procedure and 
discovered by the Investigator at  any time after the study should be reported.  All such SAEs 
must be reported to Clearside Biomedical, or its designee, within one 24 hours of the knowledge 
of the occurrence of the event.  The Investigat or must complete, sign a nd date the SAE pages, 
verify the accuracy of the information record ed on the SAE pages with the corresponding source 
documents, and send a copy by email (CLS001Safet y@medtrials.com) to Cl earside Biomedical, 
or its designee. 
Additional follow-up information, if  required or available, should all be emailed or faxed to 
Clearside Biomedical, or its designee, within one business day of receipt.  This information
should be recorded on a follow-up SAE form and placed with the original SAE information and 
kept with the appropriate secti on of the CRF and/or study file. 
Clearside Biomedical and/or its  designee is responsible for no tifying the relevant regulatory 
authorities of certain events.  It is the Principa l Investigator’s responsibility to notify and submit 
required safety information to their IRB or IEC.  This information includes, but is not limited to, 
any safety alert letter received from the Sponsor and any SAEs occurring at their investigative 
site.
Investigators will also be notified of all unexpected, serious, drug-related events, drug delivery 
system related events and study procedure relate d events (7/15 Day Safety Reports) that occur 
during the clinical trial.  Each site is responsib le for notifying its IRB or  IEC of these additional 
SAEs.  A copy of these reports must be retained at the investigative site  and file in the Trial 
Master File.
12.2.5. Follow-up of AEs and SAEs
All AEs and SAEs reported duri ng study conduct must be followe d until resolution, or until the 
Investigator assesses them as stable or chronic,  the subject withdraws consent, or the subject is 
lost to follow-up. Subjects will be followed fo r any treatment-related, drug delivery system 
related, and/or study procedure related SAEs reported at the end of participation until the 
condition stabilizes, the event is ot herwise explained, the subject is  lost to follow-up, the subject 
withdraws consent, or the subj ect experiences a fatal outcome. 
NOTE: “Resolution” means the subj ect has returned to baseline state of health, or the 
Investigator does not expect any further impr ovement in the subject’s condition or does not 
expect worsening of the AE. 
For a non-serious AE that is first identified on the last scheduled contact, the event must be 
recorded on the AE CRF with the current stat us noted, but no further follow-up needs to be 
performed unless deemed necessary by the Investigator or the Sponsor. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 59of 76 
CONFIDENTIALPost-Study SAEs: Investigators are not obligated to activ ely seek SAE information in former 
study participants; however, any new SAE reported by the subject to the Investigator that occurs 
after the last scheduled contact a nd is determined by the Investigat or to be associated with the 
use of study drug, the use of the drug delivery system, and/or study procedure, should be 
reported to the Sponsor. The Investigator should follow related SAEs identified after the last 
scheduled contact until the event has resolved or stabilized or the subject is lost to follow-up. 
12.2.6. Exposure in utero During Clinical Trials
The Sponsor must be notified of  any patient who becomes pregna nt while participating in the 
clinical trial.  Although pregnancy is not considered an AE, all pregnancies must  be followed to 
conclusion to determine their outcome.  This in formation is important for both drug safety and 
public health concerns.  It is the responsibility of the Investigator or designee to report any 
pregnancy in a subject that occurs during th e study.  Should a patient in the study become 
pregnant, the site must  complete the Exposure in utero  reporting form.  Notification should be 
made within 24 hours of awareness of the event.
It is the responsibility of the Investigator, or  designee, to report any pregnancy and the 
anticipated date of birth that occurs while rece iving, or within 30 days of discontinuing the study 
drug, via the Exposure in utero reporting form.  If the pregnancy is to be terminated, the 
anticipated date of term ination should be provided. 
If it is the partner, rather than the subject, who is found to be pregnant, after obtaining the 
partner’s consent, the Exposure in utero  reporting form should be completed with the anticipated 
date of birth/termina tion and details regarding the partne r should be entered in the narrative 
section of the form. 
The patient/partner should be followed by the Inve stigator until completion of the pregnancy.  If 
the pregnancy ends for any reason before the anticipated date of birth/termination, the 
Investigator should notify the Sponsor.  At the co mpletion of the pregnanc y, the Investigator will 
document the outcome of the pregnancy.  If the outcome of the pregnanc y meets criteria for 
immediate classification as an SAE (i.e., post- partum complications, spontaneous abortion, 
miscarriage, still birth, neonatal de ath, or congenital anomaly (eve n of an aborted fetus), the 
Investigator should follow the procedures for repo rting an SAE.  Note, elective termination of a 
pregnancy would not meet criteria as an SAE a nd in these cases a follow up pregnancy report 
should be provided by the Investigator. 
12.2.7. Complaint Handling
Clearside collects product complaints on study drugs  and drug delivery systems used in clinical 
studies in order to ensure the safety of st udy participants, monitor quality, and to  facilitate 
process and produc t improvements. 
All product complaints associated  with material packaged, labeled, and released by Clearside 
will be reported via product complaint forms. 
The complainant (the Investigator, site staff, et c.) or his/her designee is responsible for handling 
the following aspects of the product complaint pr ocess in accordance with the instructions 
provided for this study: 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 60of 76 
CONFIDENTIALxRecording a complete description of the product complain t reported and any 
associated AEs using the st udy-specific complaint forms provided for this purpose. 
xEmailing the completed produc t complaint form within 24 hours of awareness to 
Clearside at the following address:  complaints.QA@clearsidebio.com . 
xReturning a Study drug/drug delivery system  for investigation when directed by 
Clearside.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 62of 76 
CONFIDENTIALSafety endpoints are provided in Section 7.2.  Additional endpoints w ill be described in the 
statistical analysis plan.
13.5.1. Schedule of Analyses
The study duration per cohort will consist of up to 4 weeks of screening followed by a 12-week 
post-treatment period.
Cohorts 1 and 2: 
Analyses of study data for evaluating each dos e cohort will be performed after all subjects 
enrolled into the dose cohort have completed the Week 12 visit (or have been discontinued from the study prior to this visit) and the data has been locked.
Cohort 3: 
Analyses of all available safety data will be performed after the fourth subject enrolled into the 
dose cohort has completed at least Visit 3 (Week  4) (or discontinued prematurely from the study 
prior to this visit).  These analyses will include  all available study data and will be performed on 
data that has not been fully audited. 
Analysis of study data will be performed after all subjects enrolled into the dose cohort have 
completed the Week 12 visit (or have been discon tinued from the study prior to this visit) and the 
data has been locked. 
At study completion: 
Analyses of study data for comparing across dos e cohorts will be perform ed after all subjects 
enrolled into the last cohort have completed the Week 12 visit (or have been discontinued from the study prior to this visit) and the data has been locked. 
13.5.2. Safety Analysis 
The summary of adverse events (and SAEs) will be limited to TEAEs.  Treatment-emergent 
adverse events are defined as an event that emerges during treatment with CLS-AX having been 
absent pre-treatment or worsens re lative to the pre-treatment state.
For summarizing adverse events, each reported adverse event term will be coded to a preferred 
term and its corresponding system organ cla ss (SOC) using the Medi cal Dictionary for 
Regulatory Activities (MedDRA) coding dictionary.  Summary tables will be presented by dose 
cohort. 
Summary tables of TEAEs will be produced for the following categories divided into Study Eye 
TEAEs, Fellow Eye TEAEs, ocular TEAEs, non-o cular TEAEs and overall TEAEs, grouped by 
SOC and preferred term: 
xAll TEAEs. 
xAll treatment-related TEAEs. 
xAll TEAEs leading to study discontinuation. 
xAll SAEs. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 63of 76 
CONFIDENTIALxAll treatment-related SAEs. 
xAll TEAEs leading to death.
xAll TEAEs related to the SC  procedure, based on the Investigator’s assessment. 
For each summary, adverse events will be summarized by presenting the number and percentage 
of subjects reporting each event at least once,  and the total number of events reported. 
13.5.3. Secondary Safety Analyses 
Secondary safety analyses will be performed on al l subjects in the Safe ty Population.  Ocular 
safety will be assessed by evaluating IOP, BCVA and outcomes obtained from the slit-lamp biomicroscopy, indirect ophthalmoscopy, SD -OCT, fundus photography and angiography 
examinations.  Summaries w ill be provided for each dose cohort for the Study eye. 
Systemic safety will be assessed by evaluating vital signs, clinical laboratory tests, 12-lead 
electrocardiograms and concomitant medications .  Summaries will be provided for each dose 
cohort. 
13.5.4. Subgroup Analysis
No subgroup analyses are planned. 
13.5.5. Interim Analysis
The schedule of analyses of safety data from each cohort are described in Section 13.5.1 .N o  
formal statistical testing will be conducted.  All infe rential statis tics will be for descriptive 
purposes only; therefore, no adjustments will be ma de to the type 1 error rate to account for 
multiple analyses of the data.
13.5.6. Pharmacodynamic Analysis 
Not applicable.
13.5.7. Pharmacokinetic Analysis
Standard population PK pa rameters will be calculated from plas ma CLS-AX concentrations.  To 
characterize the population PK of CLS-AX, PK pa rameters will be rela ted to dose cohort.  
Analysis will be conducted according to the non linear mixed-effects approach and will provide 
estimates of population character istics that define the popula tion distribution of the PK 
parameters.
13.5.8. Procedure for Accounting for Missing Data
Any missing, unused, or spurious data will be noted in the fi nal clinical study report. 
No imputation for missing data will be  used in the Safety Populations. 
Algorithms for handling partial or incomplete dates for adverse events, concomitant medications, 
and diagnoses will be defined in the statistical analysis plan. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 64of 76 
CONFIDENTIAL14. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS
14.1. Study Monitoring
Before an investigational site can enter a subj ect into the study, a representative of Clearside 
Biomedical, Inc or its designee will a ssess the investigational study site to:
xDetermine the adequacy of the facilities and personnel. 
xDiscuss with the Investigator(s) and other personnel their responsibilities with regard 
to protocol adherence, and the responsib ilities of Clearside Biomedical, Inc. or its 
designee.  This will be documented in a Clinical Study Agreement between Clearside 
Biomedical, Inc. and the Investigator. 
xEnsure adequate training of Principal Inve stigator/sub-Investigators for use of the 
microinjector. 
During the study, a monitor from Clearside Biomedic al, Inc. or representative will have regular 
contacts (oral, written, onsite, virtual) with the investigational site, for the following:
xProvide information and support to the Investigator (s). 
xConfirm that facilities and personnel remain acceptable.
xConfirm that the investigational team is  adhering to applicable standards for 
conducting trials (e.g., ICH, GC P) the protocol, that data are being accurately 
recorded in the case report forms, a nd that study drug accountability checks are being 
performed. 
xPerform source data verification.  This in cludes a comparison of the data in the case 
report forms with the subject’s medical reco rds at the hospital or practice, and other 
source documents relevant to the study.  This will require direct access to all original 
records for each patient (e.g., clinic charts).
xRecord and report any protocol deviati ons not previously sent to Clearside 
Biomedical, Inc. or designee. 
xConfirm AEs and SAEs have  been properly documented on CRFs and confirm any 
SAEs have been forwarded to Clearside Biomedical, Inc, or designee, and those 
SAEs that met criteria for reporting ha ve been forwarded to the IRB/IEC. 
The monitor will be available between visits if the Investigator(s) or other staff needs
information or advice. 
14.2. Audits and Inspections
Authorized representatives of Clearside Biomedic al, Inc, a regulatory authority, an Independent 
Ethics Committee or an Institutional Review Board may visit the site to perform audits or inspections, including source data verification.  Th e purpose of a Clearside Biomedical, Inc audit
or inspection is to systematically and independently examine all study-related activities and 
documents to determine whether these activitie s were conducted, and da ta were recorded, 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 65of 76 
CONFIDENTIALanalyzed, and accurately reported according to th e protocol, Good Clinical  Practice guidelines of 
the International Conference on Harmonization, a nd any applicable regulatory requirements.  
The Investigator should contact Clearside Bi omedical, Inc immediatel y if contacted by a 
regulatory agency about an inspection. 
14.3. Institutional Review Board (IRB)
The Principal Investigator must obtain IRB/IEC approval for the investigation.  Initial IRB/IEC
approval, and all ma terials approved by the IRB/IEC for this  study including the subject consent 
form and recruitment materials must be maintained by the Investigator and made available for inspection. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 66of 76 
CONFIDENTIAL15. QUALITY CONTROL AND QUALITY ASSURANCE
During study conduct, Clearside or  it’s agent(s) or designee(s)  will conduct periodic monitoring 
visits to ensure the protocol and Good Clin ical Practice (GCPs) are being followed.  The 
progress of the study will also  be monitored by written, e-mail,  and telephone communications 
between personnel at the study site and the S ponsor and its agent(s) or designee(s). The 
Investigator will allow Sponsor monitors, or de signee(s), direct access to inspect all CRFs; 
subject records (source documents); signed Info rmed Consent Forms; records of study drug 
receipt, storage, and disposition; and regulatory files re lated to the study to perform verification 
and to confirm that the data recorded on CRFs is accurate. 
The study site may be subject to review by th e Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC), and/or to quality assurance audits performed by Clearside, or 
companies working with or on behalf of Clearside , and/or to inspection by appropriate regulatory 
authorities.
It is important that the Investigator(s) and th eir relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 67of 76 
CONFIDENTIAL16. ETHICS 
16.1. Ethics Review
The final study protocol, including the final vers ion of the Informed Consent Form, and other 
relevant documents, e.g., recruitment advertisements, if appli cable, must be approved or given a 
favorable opinion in writing by an IRB or IEC, as appropriate.  The Investigator must submit 
written approval to Clearside Biomedical, Inc, or designee, before he or she can enroll any subject into the study. 
The Principal Investigator is responsible for in forming the IRB or IEC of any amendment to the 
protocol in accordance with local requirements.  In addition, the IRB or  IEC must approve all 
advertising used to recruit patients for the st udy.  The protocol must be re-approved by the IRB 
or IEC upon receipt of amendments and a nnually, as local regulations require. 
The Principal Investigator is also responsib le for providing the IRB with reports of any 
reportable serious adverse drug reactions from any other study conducted with the study drug.  
Clearside Biomedical, Inc will provide this information to the Principal Investigator.
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines. 
All correspondence with the IRB/IEC should be retained in the Investigator File.   
16.2. Ethical Conduct of the Study
The study will be performed in accordance with ethi cal principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable local 
regulatory requirements and laws .  In addition, the study will be  conducted in accordance with 
the protocol. 
The Investigator will inform Clearside and/or its agent(s) immediately of any urgent safety 
measures taken by the Investigator to protect the study subjects against any immediate hazard, 
and of any serious breaches of this protocol or  of ICH GCP that the Investigator becomes aware 
of.
16.3. Written Informed Consent
The Principal Investigator(s) at each center will be responsible for ensuring that the patient is 
given full and adequate oral and written information about the natu re, purpose, possible risk and 
benefit of the study. Subjects must also be notif ied that they are free to discontinue from the 
study at any time. The informed consent document must be in compliance with ICH GCP, local 
regulatory requirements, and lega l requirements. The informed consent document used in this 
study, and any changes made during the course of  the study, must be prospectively approved by 
both the IRB/IEC and Clearside and/or its agent(s)  before use.  The subject should be given the 
opportunity to ask questions and allowed time  to consider the information provided. 
The subject’s signed and dated informed consent must be obt ained before conducting any study 
procedures. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 68of 76 
CONFIDENTIALThe Principal Investigator(s) must maintain the original, signed Informed Consent Form.  A copy 
of the signed Informed Consent Form  must be given to the subject. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 69of 76 
CONFIDENTIAL17. DATA HANDLING AND RECORDKEEPING
17.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method used in this study. 
A CRF is required and should be completed for ea ch included subject.  The completed original 
CRFs are the sole property of Clearside and should not be made available in any form to third 
parties, except for authorized representatives of Clearside or appropriate regulatory authorities, without written permi ssion from Clearside.
The Investigator has ultimate responsibility for the collection and reporting of  all clinical, safety 
and laboratory data entered on th e CRFs and any other data colle ction forms (source documents) 
and ensuring that they are accurate, authentic / original, attributable, complete, consistent, 
legible, timely (contemporaneous), e nduring and available when required. 
17.2. Inspection of Records
Clearside Biomedical, Inc or its designee will be allowed to  conduct site visits to the 
investigation facilities for the pur pose of monitoring any aspect of the study.  The Investigator 
agrees to allow the monitor to inspect the study drug storage area, study drug inventory, study 
drug accountability records, subject charts and study source documents, and any other records 
relative to study conduct.  
17.3. Retention of Records
The Principal Investigator must maintain all records relating to the study for a period of 2 years 
after the last marketing app lication approval, or if not approved 2 years following the 
discontinuance of the test article for inves tigation.  If it becomes necessary for Clearside 
Biomedical, Inc or the Regulatory Authority to  review any documentation relating to the study, 
the Investigator must permit access to such records.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 70of 76 
CONFIDENTIAL18. FINANCING AND INSURANCE
18.1. Finance
This study is supported by Cl earside Biomedical, Inc. 
18.2. Insurance
Documentation of product liability insurance is on file at Clearside and is available upon request.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 71of 76 
CONFIDENTIAL19. PUBLICATION POLICY
All information concerning CLS 1002-101 and the operations of Clear side Biomedical, Inc., such 
as patent, applications, formulas , manufacturing processes, basic sc ientific data or formulation 
information not previously published, are consider ed CONFIDENTIAL and shall remain the sole 
property of Clearside Biomedical Inc. The Investigator agrees to use this information only in 
accomplishing this study and will not use it for ot her purposes without the written consent of 
Clearside Biomedical Inc. The institutions and Inve stigators participating in  this study shall have 
no right to publish or present the results of this study without the prior written consent of 
Clearside Biomedical, Inc.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 72of 76 
CONFIDENTIAL20. REFERENCES
Ambati J, Ambati BK, Yoo SH, Ia nchulev S, Adamis AP. Age-re lated macular degeneration: 
etiology, pathogenesis, and ther apeutic strategies. Surv O phthalmol. 2003 May-Jun;48(3): 257-
93.
Busbee BG, Ho AC, Brown DM, Heier JS, Suñe r IJ, Li Z, Rubio RG, Lai P, HARBOR Study 
Group. Twelve-month efficacy and safety of 0.5 mg  or 2.0 mg ranibizumab in patients with 
subfoveal neovascular age-related macula r degeneration. Ophtha lmology. 2013 May;120(5): 
1046-1056. 
Cabral T, Lima LH, Mello LGM, Polido J, Correa ÉP, Akiyoshi Oshima, Jimmy Duong, Pedro 
Serracarbassa, Caio V. Regatieri , Vinit B. Mahajan, Rubens Belf or. Bevacizumab injection in 
patients with neovascular age-re lated macular degeneration incr eases angiogenic biomarkers. 
Ophthalmol Retina. 2018 Jan;  2(1): 31–37. doi:10.1016/j.oret.2017.04.004. 
Chylack LT, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, Wu SY. The 
lens opacities classification system III. The l ongitudinal study of cataract study group. Archives 
of ophthalmology. 1993 Jun; 111(6): 831-836. 
Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual Acuity Outcomes and Anti-Vascular 
Endothelial Growth Factor Thera py Intensity in Neovascular Ag e-Related Macular Degeneration 
Patients: A Real-World Analysis of 49,485 Ey es. Ophthalmol Retina. 2020 Jan; 4(1): 19-30 
Comparison of Age-related Macular Degenerati on Treatments Trials (C ATT) Research Group 
Writing Committee: Maureen G. Maguire, PhD, Da niel F. Martin, MD, Gui-shuang Ying, PhD, 
Glenn J. Jaffe, MD, Ebenezer Daniel, MBBS, PhD, Juan E. Grunwald, MD, Cynthia A. Toth, 
MD, Frederick L. Ferris III, MD, Stuart L. Fine, MD. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Trea tment of Neovascular Age-Rela ted Macular Degeneration: The 
Comparison of Age-Related Macular Degeneration Treatme nts Trials. Ophthalmology. 2016 
Aug;123(8): 1751-1761. 
Congdon N, O'Colmain B, Klaver CC, Klein R, M uñoz B, Friedman DS, Kempen J, Taylor HR, 
Mitchell P. Eye Diseases Prevalence Resear ch Group. Causes and prevalence of visual 
impairment among adults in the United Stat es. Arch Ophthalmol. 2004 Apr;122(4): 477-85. 
Flaxel CJ, MD, Adelman RA, MD, MPH, MBA, FACS, Bailey ST, MD, Fa wzi A, MD, Lim JI, 
MD, Vemulakonda GA, MD, Ying G, MD, PhD. Ag e-Related Macular De generation Preferred 
Practice Pattern®. Ophtha lmology. 2020 Jan;127(1): 1-65. 
Giddabasappa A, Lalwani K, Norberg R, Gukasy an HJ, Paterson D, Sc hachar RA, Rittenhouese 
K, Klamerus K, Mosyak L, Eswaraka J. Axitinib inhibits retinal and choroidal 
neovascularization in in-vitr o and in-vivo models. Exp Eye Res.  2016 Apr, 145: 373-379. 
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A. 
Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berlin er AJ, Soo Y, Anderesi M, Groetzbach G, 
Sommerauer B, Sandbrink R, Sima der C, Schmidt-Erfurth U. Intravitreal aflibercept (VEGF 
trap-eye) in wet age-related macular de generation. Ophthalmology. 2012 Dec;119(12): 2537-
2548.
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 73of 76 
CONFIDENTIALHu-Lowe D, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, 
Rewolinski DA, Yamazaki S, Wu EY, McTigue  MA, Murray BW, Kania RS, O’Connor P, 
Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of  vascular endothelial gr owth factor receptor 
tyrosine kinases 1, 2, 3. Clin Can cer Res. 2008 Nov 15; 14(22): 7272-7283. 
INLYTA (axitinib) tablets for oral administration [package insert]. New York, NY: Pfizer Labs 
(Pfizer, Inc); 2018. 
Kang S, Roh CR, Cho WK, Park KC, Yang KJ, Choi HS, So-Hee K, Roh YJ. Antiangiogenic 
effects of Axitinib, an inhibitor of vascular endot helial growth factor rece ptor tyrosine kinase, on 
laser-induced choroidal neovasc ularization in mice. Curr Ey e Res. 2013 Jan; 38(1): 119-127. 
Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach 
JV, Kopetz S. The Association of  alternate VEGF ligands with resistance to anti-VEGF therapy 
in metastatic colorectal cancer . PLoS ONE. 2013 Oct 15; 8(10): e77117. 
Lowder C, Belfort R, Lightman S, et al. Dexa methasone Intravitreal Implant for Noninfectious 
Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011 May;129(5): 545-553. 
Nakano A, Nakahara T, Mori A, Ushikubo H, Saka moto K, Ishii K. Shor t-term treatment with 
VEGF receptor inhibitors induces retinopathy of prematurity-like abnormal vascular growth in 
neonatal Rats. Exp Eye Res. 2016 Feb; 143: 120-131. 
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory 
activity in intermediate and posterior  uveitis. Ophthalmology. 1985 Apr;92(4): 467– 471. 
Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke II DW, Williams GA. 
Real-world vision in age-related macular dege neration patients treated with single anti-VEGF 
drug type for 1 year in the IRIS Re gistry. Ophthalmology. 2018 Apr;125(4): 522-528. 
5LTXHOPH0/&DPSRVဨ0ROOR()HUQiQGH]ဨ6iQFKH]/7R pical axitinib is a potent inhibitor of 
corneal neovascularization. Clinical and Experimental Ophthalmology 2018; 46: 1063–1074.  
Rofagha S, Bhisitkul RB, Boye r DS, Sadda SR, Zhang K; SE VEN-UP Study Group. Seven-year 
outcomes in ranibizumab-treated patient s in ANCHOR, MARINA, and HORIZON: a 
multicenter cohort study (SEVEN-UP) . Ophthalmology. 2013 Nov;120(11): 2292-9. 
Schmidt-Erfurth U, Kaiser PK , Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, 
Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept 
injection for neovascular age-rela ted macular degeneration: ninety -six-week results of the VIEW 
studies. Ophthalmology. 2014 Jan;121(1): 193-201. 
Singer MA, Awh CC, Sadda S, Freeman WR, An toszyk AN, Wong P, Tuomi L.  HORIZON: an 
open-label extension tria l of ranibizumab for choroidal ne ovascularization secondary to age-
related macular degeneration.  Ophthalmology. 2012 Jun;119(6): 1175-83. 
SUN Working Group. Standardization of uveitis nomen clature for reporting clinical data. Results 
from the first international workshop. Am J Ophthalmol. 2005 Sep;140(3): 509-516. 
CLS-AX (axitinib injectable suspension)  Clearside Biomedical, Inc.
CLS1002-101 (Version 5.0) Clinical Protocol
Version Date: 15 April 2022 Page 74of 76 
CONFIDENTIALThe Eye Diseases Prevalence Research Group. Pr evalence of Age-Related Macular Degeneration 
in the United States. Arch O phthalmol. 2004 Apr;122(4): 564-572. 
Thiele S, Liegl RG, König S, Siedlecki J, Langer J, Eibl K, Haritoglou C, Kampik A, Kernt M. 
Multikinase Inhibitors as a New Approach in Neovascular Age-Related Macular Degeneration 
(AMD) Treatment: In Vitro Safety Evaluations of Axitinib, Pazopanib and Sorafenib for 
Intraocular Use. Klin Monbl Augenheilkd 2013 Mar; 230(3): 247-254. 
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-
related macular degeneration and disease burde n projection for 2020 and 2040: a systematic 
review and meta-analysis. Lancet  Glob Health. 2014 Feb;2(2):e106-16. 
XIPERE (triamcinolone acetonide injectable suspension), for suprachoroidal use [package 
insert]. Alpharetta, GA: Clear side Biomedical, Inc.; 2021. 
Yuan X, Marcano DC, Shin CS, Hua X, Isenhart  LC, Pflugfelder SC, Acharya G. Ocular drug 
delivery nanowafer with enhanced therapeu tic efficacy. ACS Nano. 2015 Feb 24;9(2): 1749-58. 